DAA48 |
crystallin, mu |
Molecular |
brain |
Human |
CRYM |
12.0% Decrease Gene Expression Level |
|
DAA316 |
CTAGE family, member 4 |
Molecular |
skeletal muscle |
Human |
CTAGE4 |
4.0% Decrease Gene Expression Level |
|
DAA2424 |
C-type lectin domain family 3; member B decreases with age |
Molecular |
dermis |
Human |
CLEC3B |
18.0% Decrease DNA Methylation |
|
DAA51 |
cut-like homeobox 2 |
Molecular |
brain |
Human |
CUX2 |
19.0% Decrease Gene Expression Level |
|
DAA41 |
cyclin-dependent kinase 5 |
Molecular |
brain |
Human |
CDK5 |
7.0% Decrease Gene Expression Level |
|
DAA2423 |
cyclin-dependent kinase 5; regulatory subunit 1 decreases with age |
Molecular |
dermis |
Human |
CDK5R1 |
17.2% Decrease DNA Methylation |
|
DAA444 |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
Molecular |
skeletal muscle |
Human |
CDKN1A |
50.0% Increase Gene Expression Level |
|
DAA2063 |
cyclin-dependent kinase inhibitor 1C (p57, Kip2) decreases with age |
Molecular |
ovary |
Human |
CDKN1C |
69.3% Decrease Gene Expression Level |
|
DAA2433 |
cyclin-dependent kinase inhibitor 2B isoform 2 decreases with age |
Molecular |
mesenchymal stem cell |
Human |
CDKN2B |
16.7% Decrease DNA Methylation |
|
DAA2384 |
cyclin-dependent kinase inhibitor 2B isoform 2 increases with age |
Molecular |
dermis |
Human |
CDKN2B |
26.0% Increase DNA Methylation |
|
DAA1072 |
CYFIP2 A to I mRNA editing decreases |
Molecular |
frontal lobe |
Human |
CYFIP2 |
Increase mRNA Editing |
|
DAA38 |
cystathionine-beta-synthase |
Molecular |
brain |
Human |
CBS |
18.0% Increase Gene Expression Level |
|
DAA570 |
cysteine rich transmembrane BMP regulator 1 (chordin-like) |
Molecular |
skeletal muscle |
Human |
CRIM1 |
9.0% Increase Gene Expression Level |
|
DAA403 |
cysteine rich transmembrane BMP regulator 1 (chordin-like) |
Molecular |
skeletal muscle |
Human |
CRIM1 |
6.0% Increase Gene Expression Level |
|
DAA569 |
cytochrome c oxidase subunit VIIb |
Molecular |
skeletal muscle |
Human |
COX7B |
4.0% Decrease Gene Expression Level |
|
DAA329 |
cytochrome c, somatic |
Molecular |
skeletal muscle |
Human |
CYCS |
3.0% Decrease Gene Expression Level |
|
DAA52 |
cytochrome P450, family 2, subfamily J, polypeptide 2 |
Molecular |
brain |
Human |
CYP2J2 |
9.0% Increase Gene Expression Level |
|
DAA489 |
cytochrome P450, family 4, subfamily X, polypeptide 1 |
Molecular |
skeletal muscle |
Human |
CYP4X1 |
12.0% Increase Gene Expression Level |
|
DAA949 |
Cytomegalovirus infection incidence increases |
Pathological |
immune system |
Human |
— |
— |
|
DAA986 |
Cytotoxicity and interleukin-2 response of natural killer cells decreases |
Physiological |
natural killer cell |
Human |
— |
— |
|
DAA572 |
D-dopachrome tautomerase |
Molecular |
skeletal muscle |
Human |
DDT |
3.0% Decrease Gene Expression Level |
|
DAA56 |
DEAD (Asp-Glu-Ala-As) box polypeptide 19B |
Molecular |
brain |
Human |
DDX19B |
9.0% Decrease Gene Expression Level |
|
DAA293 |
DEAD (Asp-Glu-Ala-Asp) box polypeptide 24 |
Molecular |
skeletal muscle |
Human |
DDX24 |
3.0% Increase Gene Expression Level |
|
DAA57 |
DEAD (Asp-Glu-Ala-Asp) box polypeptide 39 |
Molecular |
brain |
Human |
DDX39 |
8.0% Increase Gene Expression Level |
|
DAA318 |
5'-3' exoribonuclease 1 |
Molecular |
skeletal muscle |
Human |
ERI1 |
4.0% Increase Gene Expression Level |
|